Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
| ▸ | MIF | P14174 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6802285 | 0.89 | ALDH1A1 (0.37) | MMP13AAK1MIFKDM4E | |
| SCHEMBL16176663 | 0.84 | AAK1 (0.41) | MMP13AAK1 | |
| SCHEMBL6805608 | 0.84 | AAK1 (0.41) | MMP13AAK1 | |
| SCHEMBL88675 | 0.83 | MMP13 (0.40) | MMP13AAK1 | |
| SCHEMBL57636 | 0.83 | MMP13 (0.40) | MMP13AAK1 | |
| SCHEMBL16176766 | 0.82 | CHRNB2 (0.40) | — | |
| SCHEMBL6810467 | 0.82 | NOTUM (0.38) | MMP13AAK1 | |
| SCHEMBL7066900 | 0.82 | SRD5A2 (0.38) | MMP13 | |
| SCHEMBL16176767 | 0.82 | CHRNB2 (0.40) | — | |
| SCHEMBL16183161 | 0.81 | L3MBTL1 (0.39) | TAS1R3TAS1R1MMP13AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040121965-A1 | Method of treating resistant tumors | WYETH HOLDINGS CORPORATION (US) | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040121965-A1 | Method of treating resistant tumors | SLC11A2, VHL, REN | TAS1R3 4477/4885TAS1R1 4317/4885MMP13 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.